Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX

The following is excerpted from a press release from PRNewswire. Read the press release in it’s entirety here.

Sangamo BioSciences, Inc. announced earlier this week that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB-FIX, the company’s zinc finger nuclease (ZFN)-mediated genome editing product candidate for the treatment of hemophilia B. Sangamo expects to initiate a Phase 1/2 clinical study (SB-FIX-1501) in adult subjects with the disease in 2016.